Asklepios BioPharmaceutical, Inc. Enters Into A Patent License Agreement With Pfizer Inc.

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Asklepios BioPharmaceutical, Inc. (AskBio), a privately-owned clinical-stage biotechnology company, announced today it has entered into a patent license agreement with Pfizer, Inc. granting Pfizer access to certain proprietary gene-delivery platform technologies developed by AskBio, for use in developing novel therapies for patients with Hepatitis C virus (HCV). HCV infection is the most common chronic blood-borne infection in the United States, with approximately 3.2 million people chronically infected.